Skip to main content

NTLA

Stock

NTLA

Stock
Health Care
Biotechnology

Performance overview

NTLA Price
Price Chart

Forward-looking statistics

Beta
1.92
Risk
68.59%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Intellia Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Company info

SectorHealth Care
IndustryBiotechnology
Employees625
Market cap$2.2B

Fundamentals

Enterprise value$587.1M
Revenue$45.6M
Revenue per employee—
Profit margin0.00%
Debt to equity15.29

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$5.23
Dividend per share—
Revenue per share$0.45
Avg trading volume (30 day)$63M
Avg trading volume (10 day)$50M
Put-call ratio—

Macro factor sensitivity

Growth-0.1
Credit+9.9
Liquidity+1.0
Inflation-6.3
Commodities-0.3
Interest Rates-2.0

Valuation

Dividend yield0.00%
PEG Ratio-1.95
Price to sales24.41
P/E Ratio-1.95
Enterprise Value to Revenue12.88
Price to book1.43

Upcoming events

Next earnings dayMay 8, 2025
Next dividend day—
Ex. dividend day—

News

Intellia Gains 29.8% in a Month: How Should You Play the Stock?

NTLA stock surges 29.8% in a month, driven by gene therapy pipeline progress and growing investor attention.

Zacks Investment Research (July 7, 2025)
Intellia Therapeutics' Rare Heart Disease Candidate Reports Liver Enzyme Spike In Phase 3 Trial, But Stays On Course

Intellia Therapeutics Inc NTLA said on Wednesday that a single, recent, asymptomatic patient has had grade 4 (severe) liver transaminase elevations (liver enzymes) based on laboratory tests in its Phase 3 MAGNITUDE study.

Benzinga (May 29, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free